The P73 gene is a homologue of the P53 tumor suppressor. Owing to its structural similarity with p53, p73 was originally considered to have tumor suppressor function. However, the discovery of N-terminal truncated isoforms with oncogenic properties showed a 'two in one' structure of its product, p73 protein. The full-length variants are strong inducers of apoptosis, whereas the truncated isoforms inhibit proapoptotic activity of p53 and the full-length p73. Thus, p73 is involved in the regulation of cell cycle, cell death and development. Moreover, it plays a role in carcinogenesis and controls tumor sensitivity to treatment. p73 is commonly expressed in tumor cells in hematological malignancies. Overexpression of p73 protein and aberrant expression of its particular isoforms, with very low frequency of P73 hypermethylation or mutations, were found in malignant myeloproliferations, including acute myeloblastic leukemia. In contrast, hypermethylation and subsequent inactivation of the P73 gene are the most common findings in malignant lymphoproliferative disorders, especially acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphomas. Assessment of P73 methylation may provide important prognostic information, as was confirmed in patients with ALL. This review summarizes some aspects of p73 biology with particular reference to its possible pathogenetic role and prognostic significance in hematological malignancies.
Introduction
The P53 tumor-suppressor gene belongs to a family that includes two recently identified homologues, P63 and P73. 1, 2 The family members are differentially involved in the regulation of cell cycle and DNA-damage-induced apoptosis. 3 Additionally, p63 and p73 have been shown to interfere with mechanisms of cell differentiation and development. 4 The product of the P53 gene, p53 protein, prevents a cell from completing the cell cycle if its DNA is damaged, protecting against malignant transformation. Although most solid tumors contain inactivating mutations of the P53 tumor suppressor, in hematological malignancies those alterations of the P53 gene are not frequent (less than 20%). 5, 6 How these tumors arise in the presence of a tumor suppressor like P53 remains to be elucidated. For several years, p53 was believed to exist as a single protein form. Recently, however, p53 has been found to exist as both N-and C-terminally truncated isoforms, although their genesis remains unclear. 7 Both full-length p53 and p53, lacking the N-terminal activation domain 1 and the C-terminal basic domain, can differentially regulate several target genes. 8 Finally, in the most recent study, it was proved that the human P53 gene contains an alternative promoter and transcribes at least six multiple splice variants, which can regulate transcriptional activity of p53. 9 For instance, the p53b isoform can bind differentially to promoters, enhancing p53 target gene expression in a promoter-dependent manner, whereas the D133p53 variant is dominant negative toward full-length p53, inhibiting p53-mediated apoptosis. In addition, another novel alternatively spliced isoform of p53 that exerts its transcriptional activity independently from p53 as an essential element of the ATRintra-S-phase checkpoint was described.
10 p53 variants were found to be differentially expressed in human breast tumors compared with normal breast tissue. 9 Their expression in hematological malignancies has not been explored so far. Thus, the biological role of those recently discovered p53 isoforms is now to be elucidated. 11 The P63 gene encodes at least six different proteins with homology to p53 and p73. Despite a structural similarity with p53, the p63 protein plays a unique developmental role in epidermal morphogenesis and differentiation (reviewed by Moll and Slade 4 ). p63 and its isoforms are differently expressed in normal tissues and neoplastic cells. 12, 13 Thus, full-length TAp63 was detected in both normal colon and in colon carcinoma, whereas N-terminal truncated DNp63, the most widely expressed isoform, was detected in squamous cell carcinomas. 13 Similarly, TAp63 isoforms are expressed in the nuclei of lymphoma cells as well as in a subpopulation of normal lymphoid cells, whereas the latter cells do not express DNp63 proteins. 13 In addition, expression of p63 was found in thymomas and non-Hodgkin's lymphomas. 12, 13 It was also shown that the tumor suppressor promyelocytic leukemia protein is a transcriptional regulator of p63.
14 The potential role of p63 in neoplastic transformation is unclear. Overexpression of TAp63 in follicular lymphoma (FL) was shown independent of the occurrence of gene abnormalities, suggesting that it may be involved in the regulation of apoptosis of tumor cells in this disease. 15 Approximately one-third of samples from patients with diffuse large cell B-cell lymphoma (DLBCL) were shown to express p63 in the nuclei, which correlated with high proliferative index, also suggesting involvement of p63 in DLBCL tumor progression. 16 Interestingly, studying a series of lymphoma cell lines, the authors found that the DNp63 isoform was expressed in only one cell line, whereas the other p63 isoforms were expressed in most cell lines analyzed.
The third member of the p53 family, p73, also presents a significant degree of sequence homology as well as functional overlap with p53. Like p53, p73 activates the transcription of several endogenous target genes, such as P21/Waf1, Mdm2, Bax, PUMA, Cyclin G, GADD4, IGF-BP3 and 14-3-3s.
Transcriptional activation of these target genes leads to the induction of cell-cycle arrest and/or apoptosis. 3, 17 Given the functional similarity between p53 and p73, it is not unreasonable to suppose that p73 might also be important for the inhibition of cancer development. However, despite similarities with p53, p73 presents significant differences in terms of regulation and function. 4, 18 In contrast to P53-deficient mice, P73-null mice show no increased susceptibility to spontaneous tumorigenesis. 19 Furthermore, P73 gives rise to a complex pattern of pro-and anti-apoptotic p73 isoforms, generated by differential splicing and alternative promoter usage. In fact, the discovery of N-terminal truncated isoforms, with oncogenic properties, showed that the P73 gene has a 'two in one' structure. Indeed, the full-length variants are strong inducers of apoptosis, whereas the truncated isoforms inhibit the proapoptotic activity of both p53 and full-length p73. Therefore, further insight into the function and regulation of these structurally and functionally diverse p73 proteins is needed to elucidate the role of p73 in human tumorigenesis.
Currently, the p73 status is extensively investigated in several neoplastic disorders, mainly solid tumors. One issue of particular interest is the correlation between p73 protein expression and tumor/cancer prognosis. P53 gene inactivation with compensatory upregulation of p73 protein was found in hepatocellular cancer. 20 Loss of heterozygosity (LOH) of the P73 gene was observed in a few cases of brain tumors. 21 Overall, in human cancers, P73 LOH has been confirmed in approximately 20% of examined patients, and only very rare P73 mutations were detected (0.6% of reported patients).
3,17 Specific antibodies against p73 protein accumulated in cancer cells were found. 22 Overexpression of p73 correlated with activation of neoangiogenesis in colorectal cancer. 11 High expression of p73 or DNp73 proteins in neoplastic cells correlated with poor prognosis in patients with hepatocellular, colorectal, breast, ovarian or lung cancers. 3, [23] [24] [25] [26] [27] In the past few years, a growing interest of p73 status in various hematological malignancies has been observed. In this review, we are summarizing the actual knowledge on the expression of the P73 gene or p73 protein in these tumors, as well as p73's possible role in tumor development and prognosis in response to therapy.
p73 protein: structure and function
The p73 protein was discovered in 1997 by Kaghad et al. 1 It is encoded by the P73 gene, located on chromosome 1, in 1p36 1 Thus, it is not surprising that both proteins bind to the same DNA sequences and transactivate the same promoters. 28 The P73 gene gives rise to multiple protein isoforms, which are generated both by alternative splicing and by the use of alternative promoters 18, [28] [29] [30] [31] [32] ( Figure 1 ). The isoforms generated by two promoters are called TAp73 and DNp73, the former contains a TA domain and the latter has a shorter amino terminus lacking the TA domain. In addition, amino-terminally truncated, transactivation-deficient p73 proteins (DTAp73) have also been described in human cancer cells. 33 These oncogenic proteins are generated by aberrant splicing (p73Dex2, p73Dex2/3, DN 0 -p73), whereas DNp73 is produced via the use of an alternative promoter within the exon/intron 3 0 . Elevated activity of the TA promoter in hepatocellular carcinoma accounts for high-level expression of both full-length TAp73 and aberrantly spliced DTAp73 variants. 34 In addition, alternative splicing generates at least nine transcripts with different carboxy termini (a, b, g, d, e, z, Z, Z1 and y). 29, 32, [35] [36] [37] Of all the p73 isoforms, p73b seems to be the most potent in transactivation and growth suppression. p73a, p73d and p73Z are less active than p73b, whereas p73g and p73e are ineffective in this respect. 29, 36 The tumor suppressor p53 regulates its own stability by transcriptionally activating its own repressor such as Mdm2, which targets p53 for degradation. Recent data suggest that TAp73 appears to promote its own turnover as well as that of other p73 forms, including DNp73. p73 also seems to undergo ubiquitin-mediated degradation, suggesting that p73 turnover is probably regulated both in a transactivation-dependent and -independent manner. 38 Depending on the presence or absence of the TA domain in the various p73 isoforms, they exert different effects on apoptosis. The balance between TAp73 and DNp73 regulates cellular sensitivity to programmed cell death ( Figure 2 ). The full-length TAp73 variants can trigger apoptosis induced by the activation of the cellular or viral oncogenes, specific DNA damage or hyperactivation of the T-cell receptor. [39] [40] [41] Moreover, as an additional mechanism, TAp73 can be activated in response to cytosolic stress via p38/MAPK pathway (reviewed by Lissy et al.
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). TAp73 induces expression of the p21 protein, which is responsible for cell-cycle arrest. Unless repair of DNA is possible, TAp73 protein induces Noxa, Puma and Bax proteins, which in turn lead to apoptotic cell death. 43, 44 The DNp73 forms have an important regulatory role, as they exert a dominant-negative effect on both p53 and TAp73 transactional activities. This inhibitory function is exerted either at the oligomerization level (for TAp73), or by competing for binding to the same DNA target sequence (for p53). p53 and TAp73 can induce expression of the DNp73 isoform, which creates a dominant-negative feedback loop that regulates the function of both p53 and TAp73. 35 The recently described N-terminally truncated, transactivation-deficient p73 isoforms, DTAp73 act as dominant-negative inhibitors of p53 and full-length TAp73. The inhibition of p53 involves competition for DNA binding, whereas TAp73 is inhibited by direct protein-protein interaction. 45 DTAp73 variants were found to be expressed in human cancer cells. 33 The upregulation of certain endogenous p73 isoforms and ectopic overexpression of transactivation-deficient DTAp73 confer resistance to p53-mediated apoptosis. 46 Furthermore, DTAp73 overexpression resulted in tumor growth in an animal model, providing evidence for its oncogenic function. 33 In summary, p73 has first been described as a structural and functional homologue of the tumor suppressor protein p53. However, the P73 gene is able to encode transcriptionally active p73 isoforms, as well as dominant negatively acting DNp73 transcript isoforms. By antagonizing the function of the full-length p73 isoforms, the amino-truncated DNp73 isoforms serve as anti-apoptotic proteins. Inherent to this unusual gene structure is the idea of a balance existing between the P73 gene products, containing the important sequences for fulfilling p53-like function, and the DNp73 products acting entirely in an opposite way. Therefore, with regard to development of human cancer, it is important to know whether p73 acts like p53 as a tumor suppressor or rather as an oncogene. Overproduction of certain p73 isoforms has been reported to promote apoptosis, similar to the case of p53, suggesting a comparable function as a tumor suppressor gene in human cancers. 47, 48 However, these data cannot easily be reconciled with data obtained from knockout mice. Indeed, in contrast to P53-deficient mice, which develop spontaneous tumors at high frequencies, 49 those lacking P73 show no increased susceptibility to spontaneous tumorigenesis. 19 These data argue against a role for P73 as tumor suppressor, but one has to keep in mind that P73 encodes two antagonistic set of proteins: TAp73 and DNp73. The knockout mice lack both of them and consequently the relative balance between TAp73 isoforms and DNp73 isoforms, inhibitor of the former, remains unchanged. Nevertheless, despite extensive studies of P73 in a variety of primary cancers, only few tumors with P73 mutation have been found. On the other hand, in a variety of tumor types, the expression of wildtype p73 is greater than in normal tissues. 50, 51 Tumor-associated upregulation of p73 and genetic data from human tumors and P73-deficient mice exclude a classical Knudson-type tumor suppressor role.
Overexpression of p73 and its specific isoforms in tumor cells, along with rare mutations or hypermethylation of P73 gene in acute myeloblastic leukemia P73 gene mutations P53 is mutated in approximately half of all cancers. In contrast to P53, mutations of P73 gene are rather rare. Patients with de novo acute myeloblastic leukemia (AML) did not show any mutations in exons 4, 6 and 7 of the P73 gene, the most often mutated exons of P53 in malignant diseases (Table 1) . 63 However, P73 mutations in exons 5 and 6 were recently found in few untreated AML patients, with the frequency of four and one out of 100 examined patients, respectively. The presence of those mutations correlated with high expression of p73 mRNA. 62 In addition, gene polymorphism has been identified in 23% of AML patients, but at a frequency similar to that observed in samples from healthy donors (25%). 63 A majority of patients with AML exhibited a monoallelic expression of P73. Thus, genetic alterations of P73 are very rare events in AML, and most probably do not play a role in development of this tumor.
P73 gene hypermethylation
Aberrant methylation, commonly occurring in neoplastic cells, is one of the mechanisms for gene inactivation. Methylation of genes responsible for programmed cell death is believed to promote malignant transformation. In two recent studies, investigation of the methylation status of the P73 gene in previously untreated patients with acute promyelocytic leukemia (APL) did not reveal any P73 methylation. 62, 75 Furthermore, Ekmekci et al. 64 reported methylation of the P73 gene in 10% of untreated AML patients studied. These findings indicate that methylation of P73 gene is rare in AML, and this epigenetic mechanism has no impact on its pathogenesis. However, most recently, Schmelz et al. 76 reported hypermethylation of P73 promoter in both AML cell lines and in primary AML cells, as a relevant target for methylation-dependent proapoptotic activity of 5-Aza-2 0 -deoxycytidine (5-Aza-CdR).
Expression of p73 protein and its isoforms
A key study evaluating expression of p73 in leukemic cells was performed by Peters et al. 67 The authors reported p73 mRNA expression in a majority of examined patients with AML and also noticed strong p73 expression in the HL-60, K562, NB4, EM3 and THP 1 leukemia cell lines, whereas the expression was low in U937 and KG-1 cells. The number of p73 transcripts was significantly higher in both AML ex vivo cells and leukemic cell lines, as compared to the normal granulocytes. This strongly suggests a role for p73 in leukemogenesis. Interestingly, however, CD34 þ progenitor cells express p73 at a high level, similar to AML cells. 67 It is likely that p73 overexpression may be related to hematopoietic precursor cell differentiation and/or very early events in malignant transformation.
Investigation of the expression pattern of six different p73 isoforms (a, b, g, d, e and z) in AML cells revealed the presence of transcripts for different p73 variants in 75% patients and in 17 out of 18 hematopoetic cell lines studied. In contrast, p73 expression was reported in 31 and 46% for normal granulocytes and lymphocytes, respectively. 68 Moreover, AML patients showed an increase in some particular isoforms (b, g, d, e, z) compared to healthy cells. Importantly, the epsilon isoform was only present in leukemic cells, but not in healthy granulocytes and lymphocytes. 68 This suggests an implication of this p73 variant in leukemic transformation of AML.
Similar results were obtained during assessment of TAp73 isoforms (a, b, g, d and e) in de novo AML patients. Whereas no p73 expression was observed in normal cells, in AML cells the short p73 isoforms were predominantly detected, with no correlation with particular types of AML according to FAB classification. 69 Thus, with very rare evidence of P73 mutation or hypermethylation, an abnormal expression of particular p73 isoforms in normal as compared to leukemic cells is the main finding in AML. Those overexpressed variants may interfere with mechanisms of cell death, proliferation or differentiation, thus influencing leukemogenesis.
p73 expression and chemosensitivity
The role of p73 in responsiveness to treatment and chemoresistance development was investigated. p53 and TAp73 can induce cell death in response to several DNA-damaging anticancer drugs. This effect can be abrogated by DNp73 or mutant p53 (Figure 2) . 77 Cells lacking TAp73 are resistant to chemotherapy similar to those lacking wild-type p53. 46 DNp73 was found to be expressed in almost all AML patients examined. The exception was APL subtype, in which the expression of DNp73 was observed in only one-third of patients. 69 The lack of DNp73 protein responsible for the inhibition of p53/p73-mediated apoptosis is likely to contribute to responsiveness of APL cells to retinoic acid treatment, followed by anthracycline-based chemotherapy.
Key message on p73 in acute myeloblastic leukemia
Mutation and hypermetylation of P73 are very rare in AML. Common p73 overexpression, with prevalence of short TAp73 isoforms, is observed. DNp73 is also expressed in almost all AML patients.
Preferential expression of p73e isoform in chronic myeloid leukemia cells

Expression of P73 gene and its protein products
Investigation of samples from chronic myeloid leukemia (CML) patients revealed the presence of p73 mRNA in almost all cases examined. 38, 43 The level of p73 mRNA decreased after allogeneic bone marrow transplantation. 67 CML cells, similar to AML cells, exhibited overexpression of the epsilon isoform, which was not detected in normal granulocytes and lymphocytes, and had rather low expression in CD34 þ progenitor cells (Table 1) . 68 Thus, a potential role of the epsilon p73 isoform in leukemic transformation is to be explored. There are no data available on P73 mutations or methylation status in CML.
Key message on p73 in chronic myeloid leukemia
Common overexpression of p73, particularly epsilon isoform, is observed. There are no data on mutation or methylation status of P73 gene.
Inactivation of P73 gene by hypermethylation and its prognostic significance in acute lymphoblastic leukemia
P73 gene mutations
Similar to other hematological malignancies, mutations in P73 gene are rare also in acute lymphoblastic leukemia (ALL). So far, only one group reported the presence of mutations localized in exons 4 and 5 of P73 gene, which were associated with lack of P73 methylation and p73 protein overexpression in three out of 120 ALL children examined.
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P73 gene hypermethylation
Despite the differences in p73 protein expression, several studies support the hypothesis that inactivation of P73 by its methylation may be important for ALL development (Table 1) . [47] [48] [49] [50] Indeed, methylation of P73 was found in 18-33% of all ALL patients (Table 1) . Silencing of P73 gene owing to methylation in similar percentage of pre-B-ALL and T-ALL cell lines was reported as well. P73 methylation was also found in childhood ALL. 53 Moreover, P73 is selectively methylated in one-third of patients with Burkitt's lymphoma. 54 Consequently, a loss of p73 mRNA expression, associated with P73 gene hypermethylation, occurred in approximately 28% of B-lineage and 43% of T-lineage cell lines tested. 78 Importantly, in contrast to malignant cells, no methylation of P73 was reported in normal lymphocytes or bone marrow cells, as well as in other healthy tissues, such as colon, kidney, brain and lungs. 41 The data presented indicate that, in contrast to AML, P73 gene methylation is a common event in ALL and may play a key role in its inactivation. Moreover, there are also evidences for prognostic value of P73 methylation status in ALL patients. Indeed, Garcia-Manero et al. 55 reported P73 gene methylation in 21% de novo ALL patients and showed its correlation with unfavorable outcome. Moreover, comparable frequency of methylated P73 gene was observed at the diagnosis and at the time of relapse.
79 P73 gene remained methylated in more than 90% relapsed ALL patients. Thus, stable methylation of P73 gene may be an important predictor of unfavorable outcome in ALL patients. These observations were also confirmed in a large study comprising 251 patients showing a prognostic value of P73 gene methylation status in ALL. 56 
Expression of p73 protein and its isoforms
A high expression of p73 protein has been reported in Molt 4 lymphoblastic cell line, Burkitt lymphoma Raji and CEM leukemic cell line. 67 On the contrary, low p73 expression in Burkitt lymphoma cells Daudi and its lack in T-lymphoblastoma Jurkat or pre-B-lymphoblastic leukemia cell line Nalm 6 was shown. p73 protein was also found to be expressed in vivo in tumor cells from approximately 60% of B-ALL and T-ALL patients. 32 In addition, p73 expression correlated with the leukemic cell differentiation stage in childhood B-ALL. Whereas p73 transcripts were detected in all examined children with prepre-B phenotype and in 61% of early B cells (C-ALL and pre-B-ALL), p73 mRNA was not detectable in mature B-cell-origin cases of ALL. 32 This suggests a potential role of p73 in the development of ALL derived from undifferentiated lymphoid precursors. Moreover, the existence of three new p73 variants in leukemic cells, named Z, Z1 and y, was reported 32 (see Figure 1 ). These variants show a remarkable expression pattern in different B-ALL types. Namely, p73Z, p73Z1 and p73y were never observed in pre-pre-B leukemias, whereas they were detectable in approximately 10-20% of pre-B-ALL and C-ALL.
Finally, p73 expression may also have a prognostic impact in ALL. The coexpression of p73 and p57 (Kip2) proteins correlated with better outcome in ALL patients. 80 The prognostic value of those proteins expression was a separate prognostic factor, independent of gene methylation status in the multivariate analysis.
Key message on p73 in acute lymphoblastic leukemia Rare P73 mutations but common P73 hypermethylation are responsible for silencing of P73 gene. Evidences for the prognostic value of P73 methylation status exist. Expression of p73 and hematological malignancies A Pluta et al p73 protein is seen in leukemic cells in a majority of ALL patients, particularly common in pre-pre-B-cell ALL.
Overexpression of p73 and its isoforms in B-cell chronic lymphocytic leukemia cells
P73 gene mutation or hypermethylation
In the only report available, no clonal LOH in the P73 gene in B-cell chronic lymphocytic leukemia (B-CLL) patients was found. 60 So far, there are no studies on P73 methylation status in B-CLL.
Expression p73 protein and its isoforms
Analysis of patients with B-CLL showed a positive correlation between p73 protein expression and progression of the disease. Total p73 mRNA was higher in B-CLL cells than in normal B-lymphocytes. Furthermore, the alpha isoform of p73 was more frequently expressed in leukemic cells than in normal CD19 þ B-lymphocytes from B-CLL patients. 61 More recently, the same group demonstrated an increased expression of both TAp73 and DNp73 variants in B-CLL patients, confirmed in 85% cases, as compared to controls (Table 1) . 60 It is possible that an increased expression of anti-apoptotic DNp73 isoforms in B-CLL cells may interfere with p53 protein, leading to its functional inactivation. In turn, this mechanism can be responsible for the antiapoptotic pattern of B-CLL tumor cells.
Key message on p73 in chronic lymphocytic leukemia
Common p73 protein expression, correlating with progression of the disease. There is increased expression of TAp73 and DNp73 variants. No P73 mutation was reported, with no data on the methylation status of P73 available.
P73 gene methylation and deletion of P73 locus in malignant lymphomas
P73 gene mutations
LOH or microsatellite instability for P73 has been reported in 25% of patients with T-cell non-Hodgkin's lymphomas (T-NHL) and 32% with B-cell NHL (B-NHL). 81 Stoffel et al. 70 detected heterozygous deletion in P73 locus in approximately one-fourth of examined patients with FL and DLBCL, which correlated with a higher proliferation status as assessed by increased Ki 67 protein expression (Table 1) .
P73 gene hypermethylation
It seems that both abnormal methylation and LOH are involved in the frequent P73 gene inactivation in B-NHL. Kawano et al. 59 described five cases of P73 gene methylation among eight examined patients with NHL, and also detected methylated P73 in a majority of lymphoma cell lines (9/10 B-cell and 2/2 T-cell lines examined). Lower frequency of P73 methylation in B-NHL (10-36%) was reported in other studies (Table 1) . 82, 83 Interestingly, the highest incidence for hypermethylation of the P73 gene among all human malignancies was reported in NK-cell NHL (94% of patients). 71 However, in a more recent study, this frequency was only 25% in patients with aggressive and chronic types of NK-cell proliferations. 84 Aberrant methylation of P73 gene has also been described in one out of three examined primary central nervous system lymphomas. 72 Most recently, tumor cells in cutaneous T-NHL were also found to show widespread promoter hypermethylation associated with P73 inactivation, among other tumor suppressor genes, such as BCL7a or PTPRG. 85 Altogether, these data indicate that P73 silencing owing to gene methylation, LOH or deletion may contribute to development and progression of NHL. Additionally, polymorphism of P73 G4C14-to-A4T14 at exon 2 is supposed to modulate the risk of NHL, at least in the Japanese population. 86 So far, there are no data available on p73 status in patients with Hodgkin's lymphoma.
Key message on p73 in NHL Frequent LOH or P73 deletion (overall in more the 25% patients) is observed. Common P73 hypermethylation silencing of the gene is evident.
Silencing of P73 gene in monoclonal gammopathies
P73 gene mutations
Investigation of the P73 status in bone marrow mononuclear cells from 68 patients with multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and plasma cell leukemia revealed the presence of monoallelic deletions of the 1p36 region in six cases, with one patient having a monosomy 1. 87 No homozygous deletions of P73 gene could be detected.
P73 gene hypermethylation
Hypermethylation of P73 gene has also been investigated in MM patients. Although no methylation of P73 gene was detected in all 13 MM patients, 65 another group reported P73 hypermethylation in 40% MM cell lines and in 12.5% MM patients examined (Table 1) . 73 Finally, in a larger study on 142 patients with MM or MGUS, P73 methylation was detected in 15 and 21% of them, respectively. 74 Thus, silencing of P73 gene by its methylation is markedly associated also with MG.
Key message on p73 in monoclonal gammopathies
Hypermethylation of P73 gene was seen in up to 21% of patients, and also rare P73 mutations.
Therapeutic targeting of p73 pathway: possible future strategies for patients with hematological malignancies Analysis of data discussed above gives a rationale for targeting the p73 pathways in order to enhance or restore chemosensitivity of hematological tumors. P73-targeted gene therapy or the modulation of p73 isoforms expression might be effective tools for biological antitumor therapy, especially in resistant malignant disease. So far, such therapeutic approaches were either not or only very poorly explored in those malignancies. Therefore, different possibilities of p73-targeted antineoplastic treatment are shortly pointed out here, based on sparse available data.
P73 gene hypomethylation
Hypermethylation of P73 in hematological malignancies can be a rationale for trials with hypomethylating agents, such as 5-Aza-CdR, being already tested in patients with different solid and hematological tumors, including myelodysplastic p73 and hematological malignancies A Pluta et al syndromes or AML. Although P73 hypermethylation is rare event in AML, 5-Aza-CdR occurred to induce p21 WAF1 expression via demethylation of P73, leading to p53-independent apoptosis in ex vivo AML cells. 76 Moreover, 5-Aza-CdR enhanced p73 and p15 expression, inhibiting growth and DNA synthesis in KG1a myeloid leukemic cell line in a dosedependent manner. 88 As presented in this review, it seems to be quite a well-documented rationale for the use of hypomethylating agents also in tumors derived from lymphoid cell lineage, including NHL, MG or ALL, which show a high rate of P73 hypermethylation.
Gene therapy with p73-expressing adenovirus
Recently, a p73b-expressing replication-deficient adenovirus (Ad-p73) has been generated. 89, 90 Infection of cancer cells with this Ad-p73 resulted in a clear increase in the level of p73b, which was associated with a significant cytotoxicity, especially in mutant p53-harboring cells. 91 Overexpression of p73b by Ad-p73 infection also increased cancer cell chemosensitivity to adriamycin. Interestingly, Ad-p73 was more efficient than Ad-p53 in enhancing the chemosensitivity of mutant p53-harboring cells. Thus, development of treatment modality utilizing Ad-p73 as cancer gene therapy agent has been proposed. 91 Ad-mediated p73 overexpression results in a strong induction of apoptosis of p53-negative pancreatic carcinoma cells. 92 This antitumor strategy, however, is likely to be feasible also in hematological malignancies.
Possible upregulation of TAp73
One of the therapeutic approaches targeting p73 might be to increase the expression of proapoptotic TAp73 variants either directly or by activating upstream transcription factors. This might be possible to achieve by utilizing small molecules strategy. This approach has not been explored yet.
Inhibition of DNp73 isoform
On the other hand, the inhibition of DNp73 isoforms, which counteracts apoptosis mediated by wild-type p53 and TAp73 and confers drug resistance to wild-type p53-harboring tumor cells, might enhance cell chemosensitivity. In this case, DNp73 can be another attractive target for molecular intervention therapy. As reported by Brummelkamp et al., 93 siRNA can effectively inhibit cellular expression of DNp73. Most recently, expression of DNp73 antisense was shown to induce apoptosis of neuroblastoma cells. 94 Such 'anti-DNp73' approaches could be theoretically applied also in hematological malignancies, especially in B-CLL, in which enhanced expression of DNp73 isoforms has already been reported. 61 Activation of p73-p53AIP1 apoptotic pathway Low-molecular-weight components were shown to restore the tumor suppressor function of mutated p73, which in turn influences p53-p73 interaction. [95] [96] [97] [98] The p53-regulated apoptosis-inducing protein 1 (p53AIP1), whose expression is induced by p53 and p73 under apoptotic conditions, has been recognized as a primary effector of wild-type p53-and TAp73-induced apoptosis. In leukemia cells, treatment with arsenic trioxide or MEK1 inhibitor activated the p73-p53AIP1 apoptotic pathway. 99 Moreover, combined treatment with MEK1 inhibitors and arsenic trioxide enhanced the affinity of phosphoacetylated p73 for the p53AIP1 promoter in vivo, as determined by chromatin immunoprecipitation experiments, leading to p53AIP1 upregulation and increased apoptosis of K562 erythroleukemia cell lines. 95 Thus, agents activating the p73-p53AIP1 apoptotic pathway may be used as another promising treatment modality for hematological malignancies.
Conclusions
Thus, overexpression of p73 protein and aberrant expression of its particular isoforms is the most common finding in myeloid malignancies, such as AML or CML. The frequency of P73 methylation as well as mutations is very low in AML. Moreover, there is a relation between expression of specific p73 isoforms, including TAp73 and DNp73 variants, and chemoresistance. The most common finding with regard to p73 status in lymphoid malignant disorders, including ALL, NHL and, to some extent, MG, is hypermethylation and subsequent inactivation of the P73 gene. Assessment of P73 methylation may provide important prognostic information, as was confirmed in patients with ALL. Interestingly, the P73 mutations (LOH, P73 deletions) are significantly frequent, exclusively in NHL patients. These data indicate that P73 status may have important clinical implications in hematological malignancies; however, further studies are needed to precisely determine its role in development of these disorders. Similar to solid tumors, either P73 gene or p73 protein may also be considered as a future biological target for antitumor strategies in several types of leukemias or lymphomas.
